MRNA: Moderna Quarterly EPS earnings growth

Public company logo of Moderna, Inc. (MRNA)

The implementation of AI algorithms for mRNA sequence synthesis in the cloud defines the strategic direction of Moderna, Inc. (MRNA). The quarterly EPS dynamics on the GURU.Markets chart confirm this trend, where 173.60 describes the current status of the metric. The high speed of drug development enabled by a flexible platform and a global cold-chain logistics network provide the company with operational resilience and supply chain protection.

Moderna Inc (MRNA) - Year-over-year net earnings per share growth for the last 12 months from 07/04/2022 to 11/14/2026

Summary analytical data breakdowns for modernatx.com (MRNA)

- share price and expert price forecast:
Stock Price Moderna|MRNA - Forecast Levels Chart
- market capitalization information:
Market Capitalization Moderna Corp|MRNA - Total Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share Moderna|MRNA - Company Net Assets|Market Cap to Net Assets Ratio modernatx.com|MRNA - Aggregate Business Assets
- company liabilities and liquidity data:
Total Debt to Capital Moderna, Inc.|MRNA - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Moderna Therapeutics|MRNA - Company Cumulative Debt|Debt to Book Capitalization Ratio Moderna Inc|MRNA - Company Long-Term Indebtedness|Company Short-Term Debt Moderna|Quick Liquidity modernatx.com
- earnings and valuation multiples indicators:
MRNA - Net Income|Expected Profit Moderna, Inc.|MRNA - Market Cap to Earnings|Forward P/E Multiple Moderna|MRNA - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Moderna Corp|MRNA - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Moderna|MRNA - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months modernatx.com|MRNA - Earnings per share growth this year|Earnings growth forecast for next year Moderna, Inc.
- revenue and sales proceeds data:
MRNA - Revenue and Sales Volume|Company Future Sales Volume Moderna Corp|MRNA - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Moderna Inc
Comprehensive company analysis:Moderna, Inc.
Flagship merchandise of Moderna, Inc.

Quarterly EPS growth measures the percentage change in net income per share, reflecting the efficiency of capital generation. For Moderna, Inc. (MRNA), quarterly EPS dynamics demonstrate the company's ability to monetize innovations despite its external dependence on contract manufacturing. Controlling this metric allows for an assessment of how outsourcing costs impact final profitability. A slowdown in growth rates signals margin erosion. Investors should interpret stagnation in this indicator as a risk of losing operational efficiency.

Key competitors

SMMT: Quarterly EPS earnings growth|Year-over-year net earnings per share trend for the last twelve months PCVX (Vaxcyte Corp)|TARS (Tarsus Pharmaceuticals Inc) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months CorMedix Inc. CRMD|Quarterly EPS earnings growth MCRB|Year-over-year net earnings per share growth for the last 12 months Spero SPRO|SCYNEXIS - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months ANTX (AN2 Bio)|PolyPid Ltd - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months ysbiopharm.com|iterumtx.com (ITRM) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months BiomX Ltd (PHGE)|Year-over-year earnings per share growth for the last twelve months Soligenix|Year-over-year earnings per share growth for the last 12 months SXTP (60degreespharma.com)|Year-over-year earnings per share growth for the last twelve months oragenics.com (OGEN)|Year-over-year net earnings per share change for the last twelve months opgen.com